Transposon-based gene delivery vectors for gene therapy

Andrea Nagy, Gergely Imre, L. Mátés

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The first gene therapy clinical trials were initiated more than two decades ago thanks to the previous development of viral vectors that allow high efficiency gene transfer into mammalian cells. Since then the application of viral gene transfer has been a successful treatment option for a variety of diseases. Hematopoietic stem cells (HSCs) represent the most frequently targeted cell population for the treatment of severe monogenic diseases as their gene therapeutic correction is a valid alternative to conventional HSC transplantation when a compatible donor is not available. Indeed, viral gene transfer was successfully applied in HSC-based ex vivo gene therapy of the blood and immune systems, albeit several studies have exposed serious adverse effects that were caused by the therapeutic vector induced inappropriate activation of proto-oncogenes. After these failures, researchers have developed new types of randomly integrating vectors that have proven safer in preclinical studies, which is consistent with interim reports of clinical trials also foreshadowing that they potentially have an improved safety profile. This review focuses on new and clinically relevant DNA transposon-based gene delivery vectors, and compares their properties with those of the old and new generation viral vectors.

Original languageEnglish
Pages (from-to)247-260
Number of pages14
JournalActa Biologica Szegediensis
Volume59
Publication statusPublished - 2015

Fingerprint

Gene therapy
gene therapy
gene transfer
transposons
Genetic Therapy
Gene transfer
Genes
Stem cells
Viral Genes
Hematopoietic Stem Cells
clinical trials
Clinical Trials
proto-oncogenes
therapeutics
cell transplantation
DNA Transposable Elements
Cells
Proto-Oncogenes
Hematopoietic Stem Cell Transplantation
Therapeutics

Keywords

  • Gene therapy
  • Non-viral vectors
  • PiggyBack
  • Sleeping Beauty
  • Transposable elements

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Transposon-based gene delivery vectors for gene therapy. / Nagy, Andrea; Imre, Gergely; Mátés, L.

In: Acta Biologica Szegediensis, Vol. 59, 2015, p. 247-260.

Research output: Contribution to journalArticle

Nagy, Andrea ; Imre, Gergely ; Mátés, L. / Transposon-based gene delivery vectors for gene therapy. In: Acta Biologica Szegediensis. 2015 ; Vol. 59. pp. 247-260.
@article{b5652ea768e54544bc7e5e33ef031d96,
title = "Transposon-based gene delivery vectors for gene therapy",
abstract = "The first gene therapy clinical trials were initiated more than two decades ago thanks to the previous development of viral vectors that allow high efficiency gene transfer into mammalian cells. Since then the application of viral gene transfer has been a successful treatment option for a variety of diseases. Hematopoietic stem cells (HSCs) represent the most frequently targeted cell population for the treatment of severe monogenic diseases as their gene therapeutic correction is a valid alternative to conventional HSC transplantation when a compatible donor is not available. Indeed, viral gene transfer was successfully applied in HSC-based ex vivo gene therapy of the blood and immune systems, albeit several studies have exposed serious adverse effects that were caused by the therapeutic vector induced inappropriate activation of proto-oncogenes. After these failures, researchers have developed new types of randomly integrating vectors that have proven safer in preclinical studies, which is consistent with interim reports of clinical trials also foreshadowing that they potentially have an improved safety profile. This review focuses on new and clinically relevant DNA transposon-based gene delivery vectors, and compares their properties with those of the old and new generation viral vectors.",
keywords = "Gene therapy, Non-viral vectors, PiggyBack, Sleeping Beauty, Transposable elements",
author = "Andrea Nagy and Gergely Imre and L. M{\'a}t{\'e}s",
year = "2015",
language = "English",
volume = "59",
pages = "247--260",
journal = "Acta Biologica Szegediensis",
issn = "1588-385X",
publisher = "University of Szeged",

}

TY - JOUR

T1 - Transposon-based gene delivery vectors for gene therapy

AU - Nagy, Andrea

AU - Imre, Gergely

AU - Mátés, L.

PY - 2015

Y1 - 2015

N2 - The first gene therapy clinical trials were initiated more than two decades ago thanks to the previous development of viral vectors that allow high efficiency gene transfer into mammalian cells. Since then the application of viral gene transfer has been a successful treatment option for a variety of diseases. Hematopoietic stem cells (HSCs) represent the most frequently targeted cell population for the treatment of severe monogenic diseases as their gene therapeutic correction is a valid alternative to conventional HSC transplantation when a compatible donor is not available. Indeed, viral gene transfer was successfully applied in HSC-based ex vivo gene therapy of the blood and immune systems, albeit several studies have exposed serious adverse effects that were caused by the therapeutic vector induced inappropriate activation of proto-oncogenes. After these failures, researchers have developed new types of randomly integrating vectors that have proven safer in preclinical studies, which is consistent with interim reports of clinical trials also foreshadowing that they potentially have an improved safety profile. This review focuses on new and clinically relevant DNA transposon-based gene delivery vectors, and compares their properties with those of the old and new generation viral vectors.

AB - The first gene therapy clinical trials were initiated more than two decades ago thanks to the previous development of viral vectors that allow high efficiency gene transfer into mammalian cells. Since then the application of viral gene transfer has been a successful treatment option for a variety of diseases. Hematopoietic stem cells (HSCs) represent the most frequently targeted cell population for the treatment of severe monogenic diseases as their gene therapeutic correction is a valid alternative to conventional HSC transplantation when a compatible donor is not available. Indeed, viral gene transfer was successfully applied in HSC-based ex vivo gene therapy of the blood and immune systems, albeit several studies have exposed serious adverse effects that were caused by the therapeutic vector induced inappropriate activation of proto-oncogenes. After these failures, researchers have developed new types of randomly integrating vectors that have proven safer in preclinical studies, which is consistent with interim reports of clinical trials also foreshadowing that they potentially have an improved safety profile. This review focuses on new and clinically relevant DNA transposon-based gene delivery vectors, and compares their properties with those of the old and new generation viral vectors.

KW - Gene therapy

KW - Non-viral vectors

KW - PiggyBack

KW - Sleeping Beauty

KW - Transposable elements

UR - http://www.scopus.com/inward/record.url?scp=84953390098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953390098&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 247

EP - 260

JO - Acta Biologica Szegediensis

JF - Acta Biologica Szegediensis

SN - 1588-385X

ER -